Prof. Rübsamen-Schaeff was CEO of AiCuris since its foundation in 2006 as a spin out from the infectious disease unit of Bayer Healthcare, also previously led by her. In March 2015 she stepped down from the CEO position and has taken over the chair of AiCuris' Scientific Advisory Board. Besides this role, Prof. Rübsamen-Schaeff supports AiCuris' management as consultant for business development and strategic aspects incl. alliance management. Before her time at Bayer, she was the scientific and executive director of the Chemotherapeutical Research Institute Georg-Speyer-Haus in Frankfurt. A chemist by training, Prof Rübsamen-Schaeff was awarded the venia legendi from the University of Frankfurt and has been professor of biochemistry since 1988. Her research interests focus on research and development of antiviral drugs (Herpes, cytomegalovirus, Human Immunodeficiency Virus, Hepatitis B), novel resistance-breaking antibiotics, as well as emerging infectious diseases and oncology. Prof. Rübsamen-Schaeff served in numerous committees such as the senate of the Fraunhofer Society, the university council of the University of Vienna and the jury for the innovation prize of the German President of State. Presently, she is a member of the board of partners of E. Merck KG and the chair of its research council, member of the supervisory board of Merck KGaA, member of the supervisory board of 4SC AG and member of the scientific panel for health under the Horizon 2020 program of the EU.
Prof. Dr. Helga Rübsamen-Schaeff
(Chair of Scientific Advisory Board)
former CEO of AiCuris